Christopher Heeschen
Overview
Explore the profile of Christopher Heeschen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
8777
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tang J, Zheng Q, Wang Q, Zhao Y, Ananthanarayanan P, Reina C, et al.
STAR Protoc
. 2025 Feb;
6(1):103635.
PMID: 39946239
We introduce a protocol for generating 3D organoids from circulating tumor cells (CTCs), enabling longitudinal functional and molecular analyses in pancreatic cancer patients, including those with unresectable disease, which constitutes...
2.
Cao Y, Qian R, Yao R, Zheng Q, Yang C, Yang X, et al.
Dev Cell
. 2025 Jan;
PMID: 39798576
Intervening in mitochondrial oxidative phosphorylation (OXPHOS) has emerged as a potential therapeutic strategy for certain types of cancers. Employing kinome-based CRISPR screen, we find that knockout of dual-specificity tyrosine phosphorylation-regulated...
3.
Wu R, Li J, Aicher A, Jiang K, Tondi S, Dong S, et al.
Adv Sci (Weinh)
. 2024 Sep;
11(42):e2308990.
PMID: 39297408
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic and lethal disease. Gasdermins are primarily associated with necrosis via membrane permeabilization and pyroptosis, a lytic pro-inflammatory type of cell death. In...
4.
Mascaraque M, Courtois S, Royo-Garcia A, Barneda D, Stoian A, Villaoslada I, et al.
J Transl Med
. 2024 Aug;
22(1):797.
PMID: 39198858
Background: We have previously demonstrated the significant reliance of pancreatic Cancer Stem Cells (PaCSCs) on mitochondrial oxidative phosphorylation (OXPHOS), which enables versatile substrate utilization, including fatty acids (FAs). Notably, dysregulated...
5.
Tang J, Zheng Q, Wang Q, Zhao Y, Ananthanarayanan P, Reina C, et al.
Cell Rep Med
. 2024 Aug;
5(9):101692.
PMID: 39163864
Pancreatic ductal adenocarcinoma (PDAC) poses significant clinical challenges, often presenting as unresectable with limited biopsy options. Here, we show that circulating tumor cells (CTCs) offer a promising alternative, serving as...
6.
Reina C, Sabanovic B, Lazzari C, Gregorc V, Heeschen C
Transl Res
. 2024 Jun;
272:41-53.
PMID: 38838851
The advent of liquid biopsies has brought significant changes to the diagnosis and monitoring of non-small cell lung cancer (NSCLC), presenting both promise and challenges. Molecularly targeted drugs, capable of...
7.
Lopez-Gil J, Garcia-Silva S, Ruiz-Canas L, Navarro D, Palencia-Campos A, Giraldez-Trujillo A, et al.
Gut
. 2024 May;
73(9):1489-1508.
PMID: 38754953
Objective: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant 'stem-like' cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness. Thus,...
8.
Liu Y, Okesola B, Osuna de la Pena D, Li W, Lin M, Trabulo S, et al.
Adv Healthc Mater
. 2024 Mar;
13(17):e2301941.
PMID: 38471128
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense and stiff extracellular matrix (ECM) associated with tumor progression and therapy resistance. To further the understanding of how stiffening of the...
9.
Liu N, Yi C, Wei L, Zhou J, Jiang T, Hu C, et al.
Cancer Cell
. 2024 Feb;
42(2):318-322.
PMID: 38350423
No abstract available.
10.
Zheng Q, Tang J, Aicher A, Bou Kheir T, Sabanovic B, Ananthanarayanan P, et al.
J Exp Clin Cancer Res
. 2023 Nov;
42(1):323.
PMID: 38012687
Background: Pancreatic ductal adenocarcinoma (PDAC) is a profoundly aggressive and fatal cancer. One of the key factors defining its aggressiveness and resilience against chemotherapy is the existence of cancer stem...